Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 2.3% Today

What is Zoetis Inc. Class A?

Zoetis (ZTS) is a leading global animal health company that develops and produces medicines and vaccines for pets and livestock. The company has shown consistent growth and outperformance in the market over the past decade.

Why is Zoetis Inc. Class A going down?

ZTS stock is down 2.3% on Nov 6, 2024 15:56

• Despite reporting strong Q3 earnings and revenue beats, Zoetis' stock experienced a bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of sustained growth.
• The comparison with other value stocks like SDZNY might have influenced some investors to shift their positions, impacting Zoetis' stock price.
• Overall, the bearish movement could be a short-term correction in response to recent positive news, presenting a potential buying opportunity for investors bullish on Zoetis' long-term prospects.

ZTS Price Chart

ZTS Technical Analysis

ZTS News

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,400 Today - Zoetis ( NYSE:ZTS )

Zoetis ZTS has outperformed the market over the past 10 years by 4.08% on an annualized basis producing an average annual return of 14.89%. Currently, Zoetis has a market capitalization of $79.87 billion.

https://www.benzinga.com/insights/news/24/11/41745215/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-4-400-today

Zoetis Q3 Earnings Beat, Companion Animal Segment Growth Gives Confidence Into 2025: Analyst - Zoetis ( NYSE:ZTS )

On Monday, Zoetis Inc's ZTS third-quarter 2024 adjusted EPS increased 16% year over year to $1.58, beating the consensus of $1.46. The animal health firm reported sales of $2.39 billion, up 11%, beating the consensus of $2.29 billion.

https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-

Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up

ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.

https://www.zacks.com/stock/news/2363644/zoetis-q3-earnings-revenues-beat-24-outlook-raised-stock-up

Zoetis ( ZTS ) Q3 Earnings and Revenues Beat Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 8.22% and 4.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2363076/zoetis-zts-q3-earnings-and-revenues-beat-estimates

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2362788/sdzny-or-zts-which-is-the-better-value-stock-right-now

Trending Today

Cardano ($ADA) Crypto Forecast: Up 25.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.4% Today

Maker ($MKR) Crypto Forecast: Up 5.2% Today

Dogecoin ($DOGE) Crypto Forecast: Up 17.5% Today

Memecoin ($MEME) Crypto Forecast: Up 12.8% Today

XRP ($XRP) Crypto Forecast: Up 11.0% Today

Kusama ($KSM) Crypto Forecast: Up 56.9% Today

Floki ($FLOKI) Crypto Forecast: Up 5.8% Today

Toncoin ($TON) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.5% Today

Zoetis Inc. Class A Price History

19.08.2024 - ZTS Stock was down 1.7%

• The bearish movement in ZTS stock today could be attributed to profit-taking by investors after a recent 15% rise in the stock price over the past 3 months.
• The mixed performance of ZTS compared to the overall market might have led some investors to reevaluate their positions in the stock.
• The comparison between ZTS and SDZNY for better value might have also influenced investor sentiment, potentially causing some to shift their investments away from ZTS.
• Despite the positive outlook for ZTS with its innovative products and business expansion efforts, short-term market dynamics and profit considerations could have driven the bearish movement in the stock today.

06.10.2024 - ZTS Stock was down 2.3%

• Despite reporting strong Q3 earnings and revenue beats, Zoetis' stock experienced a bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of sustained growth.
• The comparison with other value stocks like SDZNY might have influenced some investors to shift their positions, impacting Zoetis' stock price.
• Overall, the bearish movement could be a short-term correction in response to recent positive news, presenting a potential buying opportunity for investors bullish on Zoetis' long-term prospects.

15.03.2024 - ZTS Stock was down 7.9%

• The bearish movement in ZTS stock today can be attributed to the following factors:
• Suggestions that arthritis drugs manufactured by Zoetis may be causing illnesses in pets, leading to concerns among investors.
• Investigations by multiple law firms into potential claims against Zoetis have created legal risks for the company and prompted investors to sell their positions.
• Despite recent developments, Zoetis' core business fundamentals remain strong, offering growth prospects. This could be seen as a value investment opportunity for investors as the stock price has decreased amid market uncertainty.

08.04.2024 - ZTS Stock was down 5.1%

• Despite strong Q1 earnings and revenue exceeding expectations, Zoetis (ZTS) experienced a bearish trend in the market.
• Investors may have engaged in profit-taking activities after a recent 6% stock price surge post-earnings announcement.
• Expectations of more positive guidance or outlook from Zoetis may have led to investor disappointment, resulting in a stock sell-off.
• A comparison with industry peers like Johnson & Johnson may have revealed areas where Zoetis needs to further distinguish itself to attract investor attention.

30.04.2024 - ZTS Stock was down 1.0%

• Zoetis (ZTS) stock showed a downward trend today.
• Concerns regarding the effects of arthritis medications on animals have impacted ZTS stock negatively.
• Ongoing examinations by legal entities and financial consultants concerning potential issues in Q1 have added to investor apprehension.
• The prevailing pessimism surrounding Zoetis possibly influenced the bearish market behavior witnessed today.

12.03.2024 - ZTS Stock was down 7.8%

• Zoetis (ZTS) closed at $165.69 today, registering a -0.1% decrease from the previous close.
• Speculation around job cuts and cost reduction efforts at Zoe, a health app supported by Steven Bartlett, may have influenced negative market sentiment towards the biotech sector, impacting ZTS.
• The decline in Zoetis's short percent of float suggests possible dwindling investor confidence or short-term pessimistic positions on the stock, adding to the downward trend.
• Comparative evaluations between Zoetis and other biotech companies such as EXAS and AZN concerning growth opportunities could have spotlighted weaknesses in ZTS, potentially causing the bearish shift in its stock price.

13.03.2024 - ZTS Stock was down 7.9%

• Today's bearish movement in Zoetis Inc. (ZTS) stock can be attributed to the following factors:
• Suggestions that arthritis drugs manufactured by Zoetis may have adverse effects on pets have raised concerns among investors, leading to a sell-off of the stock.
• Multiple law firms initiating investigations into possible securities fraud at Zoetis Inc. have added to the negative sentiment surrounding the company, causing investors to offload their positions.
• The uncertainty and potential legal implications resulting from the investigations have created a lack of confidence in Zoetis's future prospects, prompting a significant downturn in the stock price.
• Investors are closely monitoring the developments related to the investigations and the impact of alleged securities violations on Zoetis Inc.'s financial performance, contributing to the heightened selling pressure on the stock.

12.03.2024 - ZTS Stock was down 6.9%

• Zoetis (ZTS) witnessed a substantial bearish movement today.
• Ongoing investigations into potential securities law violations may have caused apprehension among investors, resulting in a sell-off.
• Concerns over adverse effects associated with Zoetis' arthritis drugs for pets, Librela and Solensia, likely influenced the negative market sentiment.
• The convergence of regulatory scrutiny, negative press coverage, and potential financial repercussions from the investigations probably contributed to the sharp decline in Zoetis' stock value.

27.05.2024 - ZTS Stock was up 6.3%

• The bullish movement in ZTS today can be attributed to:
• The overall positive sentiment towards biotech and pharmaceutical stocks, emphasizing the growth potential and value of companies in these sectors.
• The increasing focus on healthcare and biotechnology sectors as investors potentially rotate away from tech stocks, leading to a surge in interest and investment in companies like Zoetis Inc.
• The mention of the Dog Vitamins Market growth potential indirectly benefiting companies like Zoetis Inc., which operates in the animal health industry and could see increased demand for its products in the future.

06.07.2024 - ZTS Stock was up 5.3%

• The company reported its financial results for the second quarter of 2024, exceeding estimates and raising its guidance for the full year 2024.
• Revenue for the second quarter of 2024 increased by 8% compared to the same period last year, showcasing strong operational growth.
• Analysts raised their target for Zoetis shares, reflecting a positive outlook on the company's performance and potential.
• Despite a declining market, Zoetis stock advanced, indicating investor confidence in the company's financial health and growth prospects.

06.07.2024 - ZTS Stock was up 5.1%

• Zoetis (ZTS) experienced a strong bullish movement today.
• The surge in stock price can be attributed to the company's impressive Q2 earnings performance, surpassing both earnings and revenue estimates.
• The positive market reaction was further fueled by Zoetis raising its outlook for 2024, indicating strong confidence in future performance.
• The beat-and-raise quarter showcased Zoetis' ability to capitalize on the growing demand for companion animal products, driving investor optimism and pushing the stock higher.

06.07.2024 - ZTS Stock was up 5.2%

• Zoetis reported better-than-expected second-quarter financial results and raised its 2024 guidance, instilling confidence in investors.
• The company beat earnings per share and revenue estimates for Q2 2024, driven by strong sales of companion animal products.
• The market reacted positively to Zoetis' "beat-and-raise" quarter, where the company exceeded expectations and provided an optimistic outlook for the future.
• Overall, the bullish movement in ZTS stock can be attributed to the company's solid performance and optimistic guidance, showcasing its resilience and growth potential in the animal health industry.